Cabergoline: Research, Dosing, and Where to Buy in 2026
A research-first profile for Cabergoline (caber), aggregating mechanism notes, transcript dosing mentions, vendor recommendations, and PubMed-indexed literature without presenting medical guidance.
Cabergoline is a research compound profiled here from named-expert transcripts and peer-reviewed literature, without medical guidance. As of July 2026, The Peptide Wiki aggregates 15 PubMed-cited papers, 2 attributed expert mentions, and 1 transcript dosing protocol for Cabergoline, each linked to its source.
- Also indexed as caber.
- 1 aggregated dosing-protocol mention from source transcripts.
- 15 PubMed-indexed citations listed in the research table below.
- 0 vendor recommendations captured from named experts.
- Evidence level in this entry is marked as research.
What is Cabergoline?
Research compound aggregated from creator and literature mentions. No direct disease-treatment claims are made on this page.
Experts on background and overview · 2 cited mentions
"vitamin B6, B5, B to keep your prolactin down or cabergoline or or some sort of dopaminergic antidepressant or modafinil"
"When caber, right? You can use caber to learn tasks."
What is Cabergoline researched for?
Dopamine D2 agonist used to suppress prolactin and improve libido/erections.
Cabergoline Dosing Protocols
The entries below are transcript-derived dosing mentions. They are preserved for research context and are not medical advice.
| Speaker | Source | Timestamp | Protocol | Evidence |
|---|---|---|---|---|
| Vigorous Steve | GH Secretagogues Vs Real GH, Managing Estradiol On Cycle,... | 00:14:43 | Per Steve's anecdotal report: starting dose 0.25mg 2-3x/week, titrate up; reported standard protocol 0.5mg 3x/week (M/W/F) | anecdotal |
Where to Buy Cabergoline in 2026
No tracked vendor recommendations for Cabergoline yet. See our vendor directory.
Side Effects and Safety
Anecdotal reports and study-level observations vary by route, dose, and individual. This page does not provide medical advice. Consult a qualified clinician before any research use.
What Experts Say
1 expert across our source library discuss Cabergoline. Each entry is that expert’s most context-rich mention: click to watch it at the exact timestamp in the original video. Quotes are also emitted as Schema.org Quotation JSON-LD for AI assistants.
-
“vitamin B6, B5, B to keep your prolactin down or cabergoline or or some sort of dopaminergic antidepressant or modafinil”
See 1 more expert mention →
-
“When caber, right? You can use caber to learn tasks.”
User Reviews
User reviews aggregator coming Q3 2026 (Reddit + YouTube comments + Discord research notes). Until then, see the expert quote section above and PubMed citations below.
Research Efficacy Snapshot
Published efficacy percentages cited in PubMed trials and named-expert reports about Cabergoline. Each line links to the original source.
- "**RESULTS**: ICD were identified in 15.9% of CAB-treated patients and 6.3% of controls, indicating a more than twofold higher prevalence and greater severity in the CAB group, although differences were not statistically significant." · Zerbinati L et al, 2026 PubMed
- "When restricted to CAB-related cases, prevalence decreased to 12.7%." · Zerbinati L et al, 2026 PubMed
- "The Questionnaire for Impulsive-Compulsive Disorders (QUIP) showed moderate sensitivity (71.4%) but low positive predictive value (41.7%)." · Zerbinati L et al, 2026 PubMed
- "No significant differences emerged in MINI or BSI-53 results, although psychiatric comorbidity was present in ~ 50% of ICD cases." · Zerbinati L et al, 2026 PubMed
- "Calculated tumor volume demonstrated moderate discriminative capacity for predicting cabergoline resistance (AUC = 0.668, p = 0.084), with an exploratory cutoff of 65.64 cm3 yielding a sensitivity of 64.3% and a specificity of 69.2%." · GarcĂa-Sáenz MR et al, 2026 PubMed
- "**PURPOSE**: Familial Isolated Pituitary Adenoma (FIPA) is a rare autosomal dominant condition associated with germline mutations in the Aryl Hydrocarbon Receptor-Interacting Protein (AIP) gene in ~ 20% of the cases." · Marino Picciola V et al, 2026 PubMed
- "Menstrual alterations occurred in 70% and galactorrhea in 63% of cases." · Carneiro MS et al, 2026 PubMed
- "After CAB withdrawal, reintroduction was necessary in all macroadenomas, 53% of microadenomas, and 23% of idiopathic HPRL." · Carneiro MS et al, 2026 PubMed
- "Following postpartum CAB withdrawal, mean serum PRL levels increased by 300% in macroadenomas, 218% in microadenomas, and 11% in idiopathic HPRL; approximately 75% of all patients experienced symptom recurrence." · Carneiro MS et al, 2026 PubMed
- "Postmenopausal PRL normalization occurred in over 40% of cases." · Carneiro MS et al, 2026 PubMed
Research and Studies
15 PubMed-indexed papers reference Cabergoline. Top 15 shown.
Legal Status
Cabergoline is presented here as a research compound. FDA approval status, scheduling, WADA status, and state-specific telehealth rules may apply. Always verify current regulatory status. Last verified: 2026-07-09.
Frequently Asked Questions
Is Cabergoline FDA-approved?
Cabergoline is presented on this page as a research compound. FDA approval status, scheduling, and state-specific rules may apply and change. Verify current regulatory status before any decision.
What dosing is reported for Cabergoline?
This page aggregates 1 dosing-protocol mention(s) from named-expert transcripts, each linked to a verbatim source timestamp. See the Dosing Protocols table above. Mentions are anecdotal, not medical advice.
How much research has been published on Cabergoline?
15 PubMed-indexed paper(s) reference Cabergoline in our current research feed. See the Research and Studies section above for citations.